# Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

> **NCT01818752** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 955 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Bortezomib
- **DRUG:** Melphalan
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01818752
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-08
- **Primary completion:** 2016-07-15
- **Final completion:** 2016-11-04
- **Target enrollment:** 955 (ACTUAL)
- **Last updated:** 2019-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818752, "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01818752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*